Kadmon is a biopharmaceutical company that discovers, develops and markets transformative therapies for unmet medical needs. Our team has a proven track record of successful drug development and commercialization. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
REZUROCK™ (belumosudil) tablets is now approved. Please click here to see full Prescribing Information for REZUROCK.